Clinical and Radiological Features of Myelin Oligodendrocyte Glycoprotein-Associated Myelitis in Adults

Overview

Journal J Clin Neurol

Specialty Neurology

Date 2022 May 19

PMID 35589317

Authors

Ki Hoon Kim

Su-Hyun Kim

Jae-Won Hyun

Ho Jin Kim

Affiliations

Soon will be listed here.

Abstract

Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have recently been established as a biomarker for MOG-antibody-associated disease (MOGAD), which is a distinct demyelinating disease of the central nervous system. Among the diverse clinical phenotypes of MOGAD, myelitis is the second-most-common presentation in adults, followed by optic neuritis. While some features overlap, there are multiple reports of distinctive clinical and radiological features of MOG-IgG-associated myelitis, which are useful for differentiating MOGAD from both multiple sclerosis and neuromyelitis optica spectrum disorder. In this review we summarize the clinical and radiographic characteristics of MOG-IgG-associated myelitis with a particular focus on adult patients.

Citing Articles

Comparison of glial fibrillary acidic protein-immunoglobulin G-associated myelitis with myelin oligodendrocyte glycoprotein-immunoglobulin G-associated myelitis.

Sun M, Liu H, Zhu B, Liu Y, Li A, Wang L Front Neurol. 2023; 14:1266067.

PMID: 38020648 PMC: 10645061. DOI: 10.3389/fneur.2023.1266067.

Clinical Usefulness of a Cell-based Assay for Detecting Myelin Oligodendrocyte Glycoprotein Antibodies in Central Nervous System Inflammatory Disorders.

Seok J, Waters P, Jeon M, Lee H, Baek S, Park J Ann Lab Med. 2023; 44(1):56-63.

PMID: 37665286 PMC: 10485852. DOI: 10.3343/alm.2024.44.1.56.

Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease.

Perez-Giraldo G, Caldito N, Grebenciucova E Front Neurol. 2023; 14:1210972.

PMID: 37483456 PMC: 10359891. DOI: 10.3389/fneur.2023.1210972.

A Case of MRI-Negative Encephalomyelitis in a Patient With Long-Term Stable Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Hwangbo J, Oh S J Clin Neurol. 2023; 19(4):422-424.

PMID: 37417441 PMC: 10329926. DOI: 10.3988/jcn.2022.0433.

References

Sechi E, Krecke K, Pittock S, Dubey D, Lopez-Chiriboga A, Kunchok A . Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler. 2020; 27(2):303-308. PMC: 7500857. DOI: 10.1177/1352458520907900. View

Beekman J, Keisler A, Pedraza O, Haramura M, Gianella-Borradori A, Katz E . Neuromyelitis optica spectrum disorder: Patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm. 2019; 6(4):e580. PMC: 6624099. DOI: 10.1212/NXI.0000000000000580. View

Zalewski N, Rabinstein A, Krecke K, Brown Jr R, Wijdicks E, Weinshenker B . Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. JAMA Neurol. 2018; 76(1):56-63. PMC: 6440254. DOI: 10.1001/jamaneurol.2018.2734. View

Macaron G, Ontaneda D . MOG-related disorders: A new cause of imaging-negative myelitis?. Mult Scler. 2019; 26(4):511-515. DOI: 10.1177/1352458519840746. View

Zhao S, Mutch K, Elsone L, Nurmikko T, Jacob A . Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult Scler. 2014; 20(12):1658-61. DOI: 10.1177/1352458514522103. View

Tantsis E, Prelog K, Alper G, Benson L, Gorman M, Lim M . Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children. Dev Med Child Neurol. 2018; 61(9):1108-1116. DOI: 10.1111/dmcn.14114. View

Kim S, Woodhall M, Kim J, Kim S, Park K, Vincent A . Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015; 2(6):e163. PMC: 4608758. DOI: 10.1212/NXI.0000000000000163. View

Pham-Dinh D, Mattei M, Nussbaum J, Roussel G, Pontarotti P, Roeckel N . Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci U S A. 1993; 90(17):7990-4. PMC: 47273. DOI: 10.1073/pnas.90.17.7990. View

Chien C, Scheel M, Schmitz-Hubsch T, Borisow N, Ruprecht K, Bellmann-Strobl J . Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Mult Scler. 2018; 25(14):1926-1936. DOI: 10.1177/1352458518815596. View

10.

Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M . Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Mult Scler. 2019; 26(8):936-944. DOI: 10.1177/1352458519849511. View

11.

Vazquez Do Campo R, Stephens A, Marin Collazo I, Rubin D . MOG antibodies in combined central and peripheral demyelination syndromes. Neurol Neuroimmunol Neuroinflamm. 2018; 5(6):e503. PMC: 6147156. DOI: 10.1212/NXI.0000000000000503. View

12.

Jurynczyk M, Messina S, Woodhall M, Raza N, Everett R, Roca-Fernandez A . Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017; 140(12):3128-3138. DOI: 10.1093/brain/awx276. View

13.

Netravathi M, Holla V, Nalini A, Yadav R, Vengalil S, Oommen A . Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. J Neurol. 2020; 268(4):1419-1433. DOI: 10.1007/s00415-020-10300-z. View

14.

Yonezu T, Ito S, Mori M, Ogawa Y, Makino T, Uzawa A . "Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler. 2013; 20(3):331-7. DOI: 10.1177/1352458513495581. View

15.

Hamid S, Whittam D, Mutch K, Linaker S, Solomon T, Das K . What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017; 264(10):2088-2094. PMC: 5617862. DOI: 10.1007/s00415-017-8596-7. View

16.

de Mol C, Wong Y, van Pelt E, Ketelslegers I, Bakker D, Boon M . Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study. J Neurol. 2018; 265(6):1310-1319. PMC: 5990581. DOI: 10.1007/s00415-018-8835-6. View

17.

Sechi E, Buciuc M, Flanagan E, Pittock S, Banks S, Lopez-Chiriboga A . Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Mult Scler Relat Disord. 2020; 47:102638. DOI: 10.1016/j.msard.2020.102638. View

18.

Hyun J, Lee H, Park J, Kim J, Min J, Kim B . Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD. Mult Scler. 2021; 28(6):989-992. DOI: 10.1177/13524585211060326. View

19.

Cobo-Calvo A, Ruiz A, dIndy H, Poulat A, Carneiro M, Philippe N . MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017; 264(9):1945-1955. DOI: 10.1007/s00415-017-8583-z. View

20.

Chen J, Tobin W, Majed M, Jitprapaikulsan J, Fryer J, Leavitt J . Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. 2018; 136(4):419-422. PMC: 5876803. DOI: 10.1001/jamaophthalmol.2017.6757. View